Severity
Low
FDA Drug recall · Reported November 8, 2023
Failed Impurities/Degradation Specifications
Glenmark Pharmaceuticals Inc., USA recalled Bisoprolol Fumarate and Hydrochlorothiazide Tablets, USP, 5mg/6.25mg, 100-count Bottle, R… - a low-severity action.
Bisoprolol Fumarate and Hydrochlorothiazide Tablets, USP, 5mg/6.25mg, 100-count Bottle, R… was recalled by Glenmark Pharmaceuticals Inc., USA in November 8, 2023. Reason: Failed Impurities/Degradation Specifications. Check the official notice for the remedy. Verify recall #D-0085-2024 with the FDA Drug before acting.
The recall
Glenmark Pharmaceuticals Inc., USA issued this low-severity FDA Drug recall-Failed Impurities/Degradation Specifications.
Sourced from official FDA Drug enforcement records. Verify recall #D-0085-2024 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0085-2024) was formally reported on November 8, 2023, with the manufacturer initiating the action on October 20, 2023. It is classified under Low severity (Class III), with a current status of Terminated. Glenmark Pharmaceuticals Inc., USA is listed as the recalling firm, operating out of Mahwah, NJ. Federal records list the affected scope as 480 100-count bottles.
The documented reason for this recall is: Failed Impurities/Degradation Specifications Distribution data in the federal record shows the product reached: Nationwide in the USA. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 3,731 children & baby products recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified low severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Low
Affected scope
480 100-count bottles
Related Recalls
6
0 from same agency
Bisoprolol Fumarate and Hydrochlorothiazide Tablets, USP, 5mg/6.25mg, 100-count Bottle, RX only, Manufactured by: Glenmark Pharmaceuticals Limited, Pithampur, Madhya Pradesh 454775, India, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430. NDC 68462-879-01
Failed Impurities/Degradation Specifications
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Low (Class III) |
| Status | Terminated |
| Recall number | D-0085-2024 |
| Date reported | November 8, 2023 |
| Date initiated | October 20, 2023 |
| Recalling firm | Glenmark Pharmaceuticals Inc., USA |
| Firm location | Mahwah, NJ |
| Affected scope | 480 100-count bottles |
| Distribution | Nationwide in the USA |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
Xishentang Dongguan Trading Co, Ltd., dba Pretty-Life, of China · 2026-07-02
Diamond Wipes International, Inc. of Chino, California · 2026-07-02
· 2026-07-02
· 2026-07-02
Sanven Technology Ltd., dba Vevor, of Rancho Cucamonga, California · 2026-07-02
Compare this recall with AMASKY Nursing Pillows Recalled Due to Risk of Serious Inju… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported November 8, 2023. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.